These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 29427652)

  • 21. Psychedelics and schizophrenia.
    González-Maeso J; Sealfon SC
    Trends Neurosci; 2009 Apr; 32(4):225-32. PubMed ID: 19269047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human abuse liability evaluation of CNS stimulant drugs.
    Romach MK; Schoedel KA; Sellers EM
    Neuropharmacology; 2014 Dec; 87():81-90. PubMed ID: 24793872
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Public-Health-Based Vision for the Management and Regulation of Psychedelics.
    Haden M; Emerson B; Tupper KW
    J Psychoactive Drugs; 2016; 48(4):243-52. PubMed ID: 27430375
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
    Dos Santos RG; Bouso JC; Alcázar-Córcoles MÁ; Hallak JEC
    Expert Rev Clin Pharmacol; 2018 Sep; 11(9):889-902. PubMed ID: 30102078
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reviewing the Potential of Psychedelics for the Treatment of PTSD.
    Krediet E; Bostoen T; Breeksema J; van Schagen A; Passie T; Vermetten E
    Int J Neuropsychopharmacol; 2020 Jun; 23(6):385-400. PubMed ID: 32170326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serotonergic psychedelics and personality: A systematic review of contemporary research.
    Bouso JC; Dos Santos RG; Alcázar-Córcoles MÁ; Hallak JEC
    Neurosci Biobehav Rev; 2018 Apr; 87():118-132. PubMed ID: 29452127
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug abuse potential evaluation in animals.
    Balster RL
    Br J Addict; 1991 Dec; 86(12):1549-58. PubMed ID: 1786486
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Taking Psychedelics Seriously.
    Byock I
    J Palliat Med; 2018 Apr; 21(4):417-421. PubMed ID: 29356590
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence and epidemiological associates of novel psychedelic use in the United States adult population.
    Sexton JD; Crawford MS; Sweat NW; Varley A; Green EE; Hendricks PS
    J Psychopharmacol; 2019 Sep; 33(9):1058-1067. PubMed ID: 30816808
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Principles of laboratory assessment of drug abuse liability and implications for clinical development.
    Carter LP; Griffiths RR
    Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S14-25. PubMed ID: 19443137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Psychedelics and the essential importance of context.
    Carhart-Harris RL; Roseman L; Haijen E; Erritzoe D; Watts R; Branchi I; Kaelen M
    J Psychopharmacol; 2018 Jul; 32(7):725-731. PubMed ID: 29446697
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treating Addiction: Perspectives from EEG and Imaging Studies on Psychedelics.
    Tófoli LF; de Araujo DB
    Int Rev Neurobiol; 2016; 129():157-85. PubMed ID: 27503452
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Psychedelics as medicines for substance abuse rehabilitation: evaluating treatments with LSD, Peyote, Ibogaine and Ayahuasca.
    Winkelman M
    Curr Drug Abuse Rev; 2014; 7(2):101-16. PubMed ID: 25563446
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 5-HT2ARs Mediate Therapeutic Behavioral Effects of Psychedelic Tryptamines.
    Cameron LP; Patel SD; Vargas MV; Barragan EV; Saeger HN; Warren HT; Chow WL; Gray JA; Olson DE
    ACS Chem Neurosci; 2023 Feb; 14(3):351-358. PubMed ID: 36630260
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predicting abuse potential of stimulants and other dopaminergic drugs: overview and recommendations.
    Huskinson SL; Naylor JE; Rowlett JK; Freeman KB
    Neuropharmacology; 2014 Dec; 87():66-80. PubMed ID: 24662599
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TCB-2 [(7R)-3-bromo-2, 5-dimethoxy-bicyclo[4.2.0]octa-1,3,5-trien-7-yl]methanamine]: A hallucinogenic drug, a selective 5-HT
    Di Giovanni G; De Deurwaerdère P
    Neuropharmacology; 2018 Nov; 142():20-29. PubMed ID: 28987938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Psychedelics as an emerging novel intervention in the treatment of substance use disorder: a review.
    DiVito AJ; Leger RF
    Mol Biol Rep; 2020 Dec; 47(12):9791-9799. PubMed ID: 33231817
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dreams and Psychedelics: Neurophenomenological Comparison and Therapeutic Implications.
    Kraehenmann R
    Curr Neuropharmacol; 2017; 15(7):1032-1042. PubMed ID: 28625125
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Using Psychedelics in Clinical Practice: Comparing Therapeutic Uses and Potential Harms.
    Tariq R
    Curr Rev Clin Exp Pharmacol; 2023; 18(2):94-109. PubMed ID: 35319407
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Guidelines and methodological reviews concerning drug abuse liability assessment.
    Balster RL; Bigelow GE
    Drug Alcohol Depend; 2003 Jun; 70(3 Suppl):S13-40. PubMed ID: 12759195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.